AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 52 min read$RXRX

Khan Najat sold $84K of RXRX

Khan Najat (CEO and President) sold 23,588 shares of RECURSION PHARMACEUTICALS, INC. (RXRX) at $3.58 on 2026-06-05 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Khan Najat
Published Jun 5, 2026, 9:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 5, 2026, 9:04 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$RXRX
Neutral
medium confidence
Mentioned
$RXRX
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$RXRXNeutralLow
01

Why it matters

The disclosed sale can influence short-term sentiment, but 10b5-1 pre-arrangement typically lowers the likelihood of it signaling new negative information.

02

Market read

A same-day insider selling print for RXRX, partially mitigated by the stated 10b5-1 plan.

03

What to watch

Consider whether other insiders also sold around the same window and whether there are concurrent clinical/regulatory updates not mentioned here.

Relevance 6/10Novelty 6/10Timing: Filed same day as the sale (2026-06-05)

Background

The article is an SEC Form 4 insider transaction disclosure for Recursion Pharmaceuticals’ CEO/President.

Company-level read

Ticker impact

$RXRXNeutralMedium confidence
Context

Recursion Pharmaceuticals CEO/President Khan Najat sold 23,588 shares in an open-market transaction disclosed via SEC Form 4.

Expected impact

Likely limited immediate price impact; watch for follow-on insider activity or concurrent fundamental catalysts.

Evidence & confidence

This is an ownership-change disclosure with transaction details, but it is explicitly under a pre-arranged 10b5-1 plan, which typically dampens signal strength versus discretionary sales.

Market effects

Sector

Adds marginal sentiment noise for biotech/clinical-stage names where insider selling can be interpreted as risk appetite.

Regional

None specific beyond US small/mid-cap biotech tape.

Global

Limited; this is company-specific insider activity.

Counterpoint

What could challenge this read

Because the sale is under a pre-arranged 10b5-1 plan, it may reflect routine liquidity rather than bearish fundamentals.

Key entities

  • company
    Recursion Pharmaceuticals, Inc.

    Issuer of the insider transaction; CEO/President sold shares via open-market sale under a 10b5-1 plan.

  • person
    Khan Najat

    CEO and President; reported the sale of 23,588 shares at $3.5806/share.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

RXRX insider trading history →

Related articles

SEP 4
$RXRXMed

RXRX Stock Steadies As AI Drug Engine Tightens Spending

Recursion Pharmaceuticals (RXRX) shares rose 5.81% on AI-driven drug discovery progress. The company reported $74.3M revenue, negative margins, and $545M in cash. Genentech optioned a neuroscience target, and RXRX cut FY26 spending to $375M, extending cash runway to early 2028. Analysts have mixed views, with an average price target of $7.22.

stockstotrade.com3 min
SEP 4
$RXRXMed

RXRX Tightens Cash Burn As AI Drug Pipeline Advances

Recursion Pharmaceuticals (RXRX) stock rose 5.96% on September 4, 2026, to $3.64, driven by AI drug discovery advancements. The company reported Q2 2026 revenue of $7.3M, a net loss of $131M, and $545M in cash. RXRX reduced its FY26 expense guidance to $375M, reflecting tighter cost management. Analysts' average price target is $7.22, with tangible clinical and partnership catalysts on the horizon.

stockstotrade.com4 min
SEP 4
$RXRXMed

RXRX Tightens Costs As AI Drug Pipeline Advances

Recursion Pharmaceuticals Inc. (RXRX) stock rose 5.83% on positive AI drug discovery progress. The company reported Q2 revenue of $74.3M, negative margins, and cash burn of -$106M, but has $545.7M in cash. RXRX guided 2026 cash operating expenses to $375M, down 40% from 2024. Analysts have mixed views, with Morgan Stanley trimming its target to $5.30 but the Street's average at $7.22.

timothysykes.com2 min
AUG 25
$RXRXMed

RXRX Stock Rallies As AI Drug Platform Tightens Cash Burn

Recursion Pharmaceuticals (RXRX) stock rose 7.23% on August 25, 2026, driven by AI-driven drug discovery progress. The company reported Q2 revenue of $7.7M, a net loss of $131M, and holds $545.7M in cash. Analysts have mixed views, with a mean price target of $7.22. RXRX is advancing its pipeline and cut FY26 cash burn guidance to $375M, extending its runway into early 2028.

stockstotrade.com3 min